Articles on dabigatran from NPS RADARArticles on dabigatran from NPS RADAR

Title Content Type Date Description
Dabigatran (Pradaxa) safety update: assess and monitor kidney function Professional publication - NPS RADAR - Brief item 2011-12-01 00:00:00 The Therapeutic Goods Administration published a Safety Advisory on 3 November 2011 regarding the risk of bleeding in people using dabigatran.
Dabigatran (Pradaxa) for stroke prevention in patients with non-valvular atrial fibrillation Professional publication - NPS RADAR - Review 2011-08-01 00:00:00 Dabigatran is an oral direct thrombin inhibitor. It is approved for the prevention of stroke in patients with non-valvular atrial fibrillation, and the prevention of venous thromboembolism after hip or knee replacement surgery.
Dabigatran (Pradaxa) for preventing venous thromboembolism after hip or knee replacement surgery Professional publication - NPS RADAR - Review 2010-04-01 00:00:00 Dabigatran is an oral direct thrombin inhibitor anticoagulant. It is approved for short-term use to prevent deep vein thrombosis and pulmonary embolism after total hip or total knee replacement surgery.

NPS RADAR: independent, evidence-based assessment of new drugs, new PBS listings and the latest research for doctors, pharmacists and other health professionals.

Date published: 2009-10-30 00:00:00

Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.

References to brands should not be taken as an endorsement by NPS.